Risk factors for monoclonal gammopathy of undetermined significance: a systematic review Maira A. Castaneda-AvilaChristine M. UlbrichtMara Meyer Epstein Review Article 08 January 2021 Pages: 855 - 863
Post-transplantation lymphoproliferative disorder after haematopoietic stem cell transplantation Francesco PegoraroClaudio Favre Review Article 06 February 2021 Pages: 865 - 878
Hepcidin and other indicators of iron status, by alpha-1 acid glycoprotein levels, in a cohort of Mexican infants Eugenia MendozaXimena DuqueHomero Martinez Original Article 30 January 2021 Pages: 879 - 890
Curcuminoids supplementation ameliorates iron overload, oxidative stress, hypercoagulability, and inflammation in non-transfusion-dependent β-thalassemia/Hb E patients Suneerat HatairakthamPatarabutr MasaratanaRuchaneekorn W. Kalpravidh Original Article 03 January 2021 Pages: 891 - 901
Influence of UGT1A1 promoter polymorphism, α-thalassemia and βs haplotype in bilirubin levels and cholelithiasis in a large sickle cell anemia cohort Jéssica V. G. F. BatistaGabriela S. ArcanjoMarcos A. Bezerra Original Article 01 February 2021 Pages: 903 - 911
Numb chin syndrome in sickle cell disease: a case series of Jamaican patients Zachary RamsayChristine Hammond GabbadonMonika Asnani Original Article 22 January 2021 Pages: 913 - 919
Alpha thalassemia, but not βS-globin haplotypes, influence sickle cell anemia clinical outcome in a large, single-center Brazilian cohort Betânia Lucena Domingues HatzlhoferDiego Antonio Pereira-MartinsMarcos André Cavalcanti Bezerra Original Article 13 February 2021 Pages: 921 - 931
Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series Anastasia MartynovaVictor ChiuIlene Ceil Weitz Original Article Open access 09 January 2021 Pages: 933 - 939
Temporal trends and outcome of splenectomy in adults with immune thrombocytopenia in the USA Antoine FinianosHata MujadzicMarwan S. Abougergi Original Article 09 February 2021 Pages: 941 - 952
The prognostic value of the Fibrinogen-Albumin Ratio Index in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes treated with azacitidine Masahiro AkimotoAki SakuraiTomonori Nakazato Original Article 01 February 2021 Pages: 953 - 957
Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group Esther SchulerEva-Maria Wagner-DrouetOn behalf of the German Cooperative Transplant Study Group Original Article Open access 16 November 2020 Pages: 959 - 968
Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis Dipenkumar ModiVijendra SinghJoseph P. Uberti Original Article 16 February 2021 Pages: 969 - 978
Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma S. BernardL. HachonCatherine Thieblemont Original Article Open access 19 February 2021 Pages: 979 - 986
Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort Florian BoucletAnne CallejaRomain Guièze Original Article 25 January 2021 Pages: 987 - 993
Circulating low CD4+/CD8+ ratio is associated with poor prognosis in Waldenstrom macroglobulinemia patients Xin CaoYi-Lin KongWei Xu Original Article 02 March 2021 Pages: 995 - 1002
Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R/R B-ALL patients: a systematic review and meta-analysis Linhui HuAlice CharwudziZhimin Zhai Original Article 15 February 2021 Pages: 1003 - 1012
Cure rate in the elderly patients with diffuse large B cell lymphoma deteriorates after the age of 80—results from a single-center survey Felix FreudenbergerAnke OhlerGeorg Hess Original Article Open access 25 February 2021 Pages: 1013 - 1021
Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients Eva González-BarcaFrancisco Javier Capoteon behalf of the GELTAMO (Spanish Lymphoma Group) and GOTEL (Group of Oncology for Therapy and Study of Lymphomas) Original Article 04 May 2020 Pages: 1023 - 1029
Age-dependent increase of treatment-related mortality in older patients with aggressive B cell lymphoma: analysis of outcome, treatment feasibility, and toxicity in 1171 elderly patients with aggressive B cell lymphoma—data from phase II and III trials of the DSHNHL (German High-Grade Non-Hodgkin’s Lymphoma Study Group) Florian ZettlMarita ZiepertLorenz Trümper Original Article Open access 26 November 2020 Pages: 1031 - 1038
Dynamic evaluation of the prognostic value of 18F-FDG PET/CT in extranodal NK/T-cell lymphoma, nasal type Pengpeng XuRui GuoWeili Zhao Original Article 26 February 2021 Pages: 1039 - 1047
Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial James RussellAngela CollinsGeorge A. Follows Original Article Open access 27 February 2021 Pages: 1049 - 1058
Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group Federico VozellaA. SiniscalchiM. T. Petrucci Original Article 02 February 2021 Pages: 1059 - 1063
Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study Shinsuke IidaTakayuki IshikawaShigeki Ito Original Article Open access 18 February 2021 Pages: 1065 - 1077
Frequent occurrence of hypophosphatemia among multiple myeloma patients treated with elotuzumab: a single clinic retrospective study Bernard RegidorRegina SwiftJames R. Berenson Original Article 25 November 2020 Pages: 1079 - 1085
IgM-MGUS and associated membranoproliferative glomerulonephritis during IVIG administration Johannes RuheHermann-Josef GröneMartin Busch Letter to the Editor Open access 04 May 2020 Pages: 1087 - 1088
Strongyloides stercoralis hyperinfection syndrome in mantle cell lymphoma in post-transplant setting Kamal Kant SahuKedar MahagaokarJan Cerny Letter to the Editor 06 May 2020 Pages: 1089 - 1091
Single-drug vinorelbine as a salvage re-induction regimen for 4 consecutive pediatric patients with relapsed anaplastic large-cell lymphoma in a single children’s institution Qing YuanQiao HeYi-Jin Gao Letter to the Editor 13 July 2020 Pages: 1093 - 1095
Successful treatment of EBV-related lymphoproliferative disease after heart transplantation with autologous hematopoietic stem cell transplantation despite transient heart failure associated with engraftment syndrome Megumi YasunagaYohei YasudaMineo Kurokawa Letter to the Editor 06 August 2020 Pages: 1097 - 1100
CD3+/CD56+ EBV+ neoplasms in the nose and upper aerodigestive tract: potential misdiagnosis of plasma cell malignancies as NK/T cell lymphoma Rex Au-YeungFlorence LoongYok-Lam Kwong Letter to the Editor 29 August 2020 Pages: 1101 - 1104
Ruxolitinib treatment improves muscle mass in patients with myelofibrosis Marko LucijanicDavor GalusicRajko Kusec Letter to the Editor 01 September 2020 Pages: 1105 - 1106
Revealing the true face behind the mask of ALK-positive anaplastic large cell lymphoma (ALCL) Hannah EisfeldStefan KircherKarin G. Schrenk Letter to the Editor Open access 08 September 2020 Pages: 1107 - 1109
Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients P. ZappasodiM. BrocinerL. Arcaini Letter to the Editor 11 November 2020 Pages: 1111 - 1113